relapsed CLL/SLL - study of interest: FCR+btk-inhib. v. BR+btk-inhib.

[Guest guest]

Bruton's Tyrosine Kinase (Btk) Inhibitor in Combination With Chemotherapy in

Subjects [Participants] With CLL/SLL

Link to protocol details and locations: http://bit.ly/fKPwlp

Comment: Following this safety study (n=50) we might expect the sponsor will

test the winner against the same chemo without the btk-inhibitor as a basis

for marketing approval.

.. However, if there's a big winner here (relative to historical controls)

will a randomized study remain feasible . that is, would patients

participate?

That said, this study seems worthy of consideration in a circumstance where

FCR or BR is recommended for you . my assumption being that there's genuine

uncertainty about which chemo protocol is better in the CLL/SLL relapse

setting, and also encouraging reports so far on the btk-inhibitor, which

appears to have a favorable toxicity profile compared to other agents.

It would be nice to see this studied in similar ways in the other indolent

lymphomas, first and second-line.

See for more on the Btk-inhibitor, including links to other trials:

http://www.lymphomation.org/treatment-pipeline.htm#btk-inhibitor

All the best,

~ Karl

Patients Against Lymphoma

Bcc: advisors for input